Gothenburg October 26, 2016 - At the Annual
General Meeting ("AGM") of Immunicum AB (publ), reg.no 556629-1786,
the following resolutions were mainly adopted. For more detailed
information on the content of the resolutions, please see the press
release published on September 26, 2016 and the complete notice to
the AGM. The notice to the AGM and complete motions on the
resolutions are available at the company's website,
www.immunicum.se.
Adoption of the balance sheet and
income statement
The AGM adopted the
company's balance sheet and income statement.
Disposition regarding the
company's results
The AGM resolved that no
dividend shall be paid for the financial year 2015/2016. The AGM
further resolved that the company's accumulated loss shall be
appropriated so that SEK 114,653,179 be settled against the share
premium reserve and that the remaining SEK 137,882,043 be carried
forward.
Board of Directors and
Auditor
The AGM discharged the Board members
and the CEO from liability for the financial year 2015/2016.
The AGM resolved that the Board of Directors shall
comprise seven Board members.
The AGM re-elected Board members Agneta Edberg,
Martin Lindström, Magnus Nilsson and Magnus Persson. Bengt Furberg
declined re-election. The AGM resolved to elect Steven Glazer,
Charlotte Edenius and Kerstin Valinder Strinnholm as new Board
members. Agneta Edberg was re-elected as Chairman of the Board.
The AGM resolved to appoint the registered public
accounting firm KPMG as Auditor for the period until the next
Annual General Meeting. KPMG has announced that the authorized
public accountant Jan Malm shall be the Auditor in Charge.
Fees to the Board of Directors
and Auditor
The AGM decided that remuneration
to the Board shall be a maximum of SEK 1,185,000, based on a fiscal
year comprising a period of twelve months, to be distributed as
follows: Chairman SEK 295,000, the other members SEK 125,000 each,
a member who is chairman of the audit committee SEK 35,000, a
member who is a member of the audit committee SEK 15,000, a member
who is chairman of the scientific committee SEK 50,000, a member
who is a member of the scientific committee SEK 25,000. No other
remuneration for committee work shall be paid.
The AGM further resolved that, in addition to
directors' fees, the Board as a whole can be paid a maximum of SEK
100,000 for such work that can be regarded as outside of the normal
board work and that Board members may be allowed to, through his or
her own company, invoice fees given that this is cost neutral for
the company.
The AGM decided that remuneration to the auditor
shall be paid according to approved invoices.
Authorization for the Board of
Directors to decide on new share issues
The AGM resolved to authorize the Board of
Directors to, on one or several occasions during the period until
the next Annual General Meeting, with or without deviation from the
shareholder's preferential rights, resolve on new share issues of a
maximum of 5,040,000 shares. If fully utilized, the authorization
entails a dilution equivalent to approximately 16.3 per cent of the
company's share capital and number of votes.
Decision to change the fiscal
year and to amend the Articles of Association
The AGM resolved to change the fiscal year of the
company to calendar year as well as to shorten the current fiscal
year to cover the period 1 July 2016 up to and including 31
December 2016.
The AGM further resolved to amend the Articles of
Association so that the company's financial year shall be calendar
year and that it shall no longer be possible to appoint deputy
directors of the Board.
Decision on updated principles
for appointing the Nomination Committee
The AGM resolved to update the principles for
appointing the Nomination Committee in accordance with the
Nomination Committee's proposal.
Decision on guidelines for
remuneration to senior executives
The AGM resolved on guidelines for remuneration to
senior executives so that the limits of variable remuneration were
increased from a maximum of three ordinary monthly wages to a
maximum of 35 per cent of the ordinary fixed remuneration.
For more information, please
contact:
Agneta Edberg, Chairman of the Board,
Immunicum
Ph: +46 (0)70 555 75 18
edberg.agneta@gmail.com
The company's Certified Advisor is Redeye
AB
Ph: +46 (0)8 545 013 31.
www.redeye.se
About Immunicum AB (publ)
Immunicum AB (publ) develops cancer immune primers
for the treatment of tumor diseases. A phase II clinical trial for
the company's most advanced product - INTUVAX® against kidney
cancer - has been initiated. The project portfolio contains
additional clinical phase I/II studies in liver cancer and in
gastrointestinal stromal tumors (GIST). Immunicum is listed on
First North Premier. www.immunicum.se.
The information in this press
release is disclosed pursuant to the Nasdaq First North's Rulebook.
The information was released for public disclosure through the
agency of the company's contact person on 26 October, 2016 at 14:00
CET.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024